Evidence for the impact of pharmacogenetic factors on drug effects has markedly increased in recent years. However, the inclusion of pharmacogenetics in prescription decisions in clinical practice lags behind the initial high expectations for this new field of clinical pharmacology.
This webinar will address the strengths and limitations of pharmacogenetics for modern pharmacotherapy. Prof. Stefan Russmann, clinical pharmacologist and pharmacoepidemiologist, will discuss the latest scientific evidence supporting pharmacogenetics-guided pharmacotherapy, share his first-hand experience with implementing pharmacogenetics in clinical practice, and provide an overview of how pharmacogenetics may change drug development and prescription in the future.
Prof. Russmann will cover drug-drug-gene interactions, the implementation and benefits of pharmacogenetic panel testing, CYP2C19 and clopidogrel therapy, CYP2D6 and tamoxifen therapy, and DPYD and chemotherapy. In addition, the latest developments in DPYD testing from Agena Bioscience will be presented.
Dr. Robin Everts from Agena Bioscience will follow with an overview of Agena’s MassARRAY® System and the latest developments in DPYD testing.